BTA 0.00% 57.0¢ biota holdings limited

new research confirms relenza should be no 1

  1. 8,789 Posts.
    lightbulb Created with Sketch. 14

    ''As a result of this outbreak, researchers suggest actively screening patients for oseltamivir-resistant H1N1 viruses, and altering treatment guidelines to include zanamivir (Relenza, GlaxoSmithKline) alone, rather than dual treatment with oseltamivir in H1N1 patients, since the H1N1 virus is still susceptible to zanamivir.''

    '' Zanamivir should be considered as first-line therapy for influenza in patients with lymphopenic hematological conditions and uptake of influenza vaccination encouraged to further reduce the number of susceptible individuals.''

    http://infectonews.wordpress.com/2011/01/27/evidence-of-person-to-person-transmission-of-oseltamivir-resistant-pandemic-influenza-ah1n1-2009-virus-in-a-hematology-unit/

 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.